Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine.

被引：0
|
作者：
Keating, MJ
Byrd, J
Rai, K
Flinn, I
Jain, V
Binet, JL
Bolin, R
Hillmen, P
Hutchinson, M
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3118
引用
收藏
页码：705A / 705A
页数：1
相关论文
共 50 条
  • [21] Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study
    Dyer, MJS
    Buckby, E
    Fermahan, P
    Walewska, R
    Kennedy, B
    BLOOD, 2005, 106 (11) : 830A - 830A
  • [22] A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901.
    Rai, KR
    Byrd, JC
    Peterson, BL
    Larson, RA
    BLOOD, 2002, 100 (11) : 205A - 206A
  • [23] T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
    Kiaii, S
    Mozaffari, F
    Lundin, J
    Rezvany, R
    Chudhury, A
    Mellstedt, H
    Osterborg, A
    BLOOD, 2004, 104 (11) : 689A - 689A
  • [24] Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Nguyen, DD
    Cao, TM
    Dugan, K
    Starcher, SA
    Fechter, RL
    Coutre, SE
    CLINICAL LYMPHOMA, 2002, 3 (02): : 105 - 110
  • [25] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL)
    Rawstron, AC
    Davies, FE
    Evans, PA
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Morgan, GJ
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 46 - 46
  • [26] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL).
    Rawstron, AC
    Davies, FE
    Evans, P
    Morgan, GJ
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Hillmen, P
    BLOOD, 1997, 90 (10) : 2356 - 2356
  • [27] Evolution of a true B-cell chronic lymphocytic leukaemia (B-CLL) in a diffuse immunocytoma after treatment with fludarabine.
    Bernasconi, P
    Paulli, M
    Orlandi, E
    Perfetti, V
    Giardini, I
    Zibellini, S
    Vanelli, L
    Tenore, A
    Boni, M
    Cavigliano, PM
    Algarotti, A
    Brusamolino, E
    Lazzarino, M
    BLOOD, 2005, 106 (11) : 324B - 324B
  • [28] Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Osterborg, A
    Mellstedt, H
    Keating, M
    MEDICAL ONCOLOGY, 2002, 19 (Suppl 2) : S21 - S26
  • [29] Campath-1H in refractory B-CLL -: Complete remission despite p53 gene mutation.
    Stilgenbauer, S
    Scherer, K
    Kröber, A
    Bullinger, L
    Höchsmann, B
    Mayer-Steinacker, R
    Bunjes, D
    Döhner, H
    BLOOD, 2001, 98 (11) : 771A - 771A
  • [30] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
12345